| Document |
Document Title |
|
WO/2022/260132A1 |
The present invention addresses the problem of providing an effective cancer treatment method. Provided is a cancer treatment method in which are combined a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody, etc...
|
|
WO/2022/258052A1 |
Disclosed is a heterocyclic lactam compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, as represented in formula (I), wherein the compounds have an inhibitory effect on RIPK1 and the definition of ea...
|
|
WO/2022/261336A1 |
Methods of drug target and therapeutic compound discovery utilizing human disease-related phenotypes in hibernating mammals followed by target validation. Drug target identification of genes is accomplished by identification of adaptatio...
|
|
WO/2022/260335A1 |
Provided are: a pharmaceutical composition, food composition, or feed composition for improving the intestinal microbial population comprising galactose, and for reducing body weight; and use thereof for preventing and/or treating and/or...
|
|
WO/2022/260050A1 |
The purpose of the present invention is to improve the stability of a liquid preparation for ophthalmic use that comprises brimonidine and/or a salt thereof. The present inventors found that the stability can be improved by adding an ant...
|
|
WO/2022/260016A1 |
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically ...
|
|
WO/2022/259884A1 |
Provided is a novel skin care composition suited for cell activation. A skin care composition according to the present disclosure contains an ultraviolet wavelength-converting substance and an alkylene oxide derivative.
|
|
WO/2022/260162A1 |
The present invention addresses the problem of providing a means that is useful for research and development of the NASH mechanism and a therapeutic method. Also, the present invention addresses the problem of providing a prophylactic an...
|
|
WO/2022/259848A1 |
[Problem] To provide a valproic acid derivative for improving the disadvantages or faults associated with using valproic acid itself as medicine. [Solution] Provided is a polymeric compound of valproic acid that is a block copolymer cont...
|
|
WO/2022/253795A1 |
The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): 5 I wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, prefe...
|
|
WO/2022/253326A1 |
The present invention relates to the technical field of medicine, and relates to an NLRP3 inflammasome inhibitor and an application thereof. The present invention particularly relates to a compound represented by general formula (I) or a...
|
|
WO/2022/256215A1 |
The present disclosure encompasses a solid state form of Centanafadine HCl, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/253270A1 |
A substituted triazinylmethylcycloalkylcarboxylic acid derivative having a structure as shown in formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use...
|
|
WO/2022/255399A1 |
The present invention pertains to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof and a pharmaceutical use thereof, for example, a pharmaceutical composition that is to be used for preventing ...
|
|
WO/2022/256529A1 |
The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (...
|
|
WO/2022/255273A1 |
Provided is an S1P ligand-bound nucleic acid complex that is delivered to a desired organ to regulate the expression or editing of a target gene, a transcript thereof or a translation product thereof. This S1P ligand-bound nucleic acid...
|
|
WO/2022/255250A1 |
The present invention provides a means for promoting muscle regeneration from muscle damage. Specifically, a compound (excluding histamine) having histamine H3 receptor agonist activity or a salt thereof is used as an active ingredient.
|
|
WO/2022/255499A1 |
The purpose of the present invention is to provide a novel AMP-activated protein kinase activator. The present invention relates to a compound represented by formula (I): [wherein each symbol is as defined in the description], or a salt ...
|
|
WO/2022/255440A1 |
The invention provides anti-DDR2 antibodies that binds to DDR2, and methods of using the same. The invention further provides isolated nucleic acids encoding the anti-DDR2 antibodies, host cells comprising the same, and methods of produc...
|
|
WO/2022/255384A1 |
Provided is a pharmaceutical composition which can exhibit an anti-tumor effect more potently, more efficiently, more sustainably, and/or in a wider range. A composition comprising a hyaluronic acid derivative having a hydrophobic group ...
|
|
WO/2022/255282A1 |
The present invention provides: a dynamic visual acuity-enhancing composition comprising eugenol as an active ingredient; a composition for suppressing reductions in dynamic visual acuity in the elderly, said composition comprising, as a...
|
|
WO/2022/255346A1 |
The purpose of the present invention is to provide a method for treating or preventing a disease or the like which pertains to mitochondrial function by using a substance which pertains to the decline or improvement of mitochondrial func...
|
|
WO/2022/255955A1 |
The present invention relates to ((1S,9S)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quina
zolinyl]methyl}-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dien-6-one) compound and related derivatives. The compound of the invention is a C...
|
|
WO/2022/255790A1 |
The present disclosure relates to medical use of a compound of chemical formula 1 for treatment or prevention of pulmonary fibrosis. The present disclosure also relates to combination therapy with the compound of chemical formula 1 and n...
|
|
WO/2022/255276A1 |
The purpose of the present invention is to provide a composition for improving or suppressing decline of social healthiness and a method for improving or suppressing decline of social healthiness. The present invention pertains to a comp...
|
|
WO/2022/255248A1 |
The purpose of the present disclosure is to develop a new combination therapy that exerts a superior antitumor effect as compared to administration of an anti-CD26 antibody alone. In order to assess both the function of an immune checkpo...
|
|
WO/2022/256379A1 |
Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions and kits described herein. The pharmaceutical compositions described herein are...
|
|
WO/2022/250085A1 |
A new target molecule for pruritis has been discovered, and a novel means for eliminating pruritis is provided. This agent for preventing or ameliorating intractable pruritis uses a C3a receptor antagonist as an active ingredient.
|
|
WO/2022/248835A1 |
The present invention relates to methods for increasing the anti-tumor immune response in a patient suffering from cancer, a method for the treatment or prophylaxis of cancer, and a method for enhancing the effectiveness of an inhibitor ...
|
|
WO/2022/250027A1 |
This anti-inflammatory agent for the intestinal cells of a non-human animal is characterized by containing cashew nut shell oil, heat-treated cashew nut shell oil, anacardic acid, cardanol and/or cardol, and vitamin K.
|
|
WO/2022/251386A1 |
A method of treatment is disclosed. The method comprises administering to a human subject having or at risk of developing a disease associated with decreased expression of one or more genes encoding cytochrome P450, an effective amount o...
|
|
WO/2022/250072A1 |
The present invention provides a therapeutic agent for cardiac disease that includes an oligonucleotide having one or more nucleotides represented by formula I or formula II below: (in formulas I and II: Base represents a 2-oxo-1, 2-dihy...
|
|
WO/2022/250050A1 |
Provided is a double-stranded nucleic acid complex that exhibits a reduced toxicity without a loss of effectiveness. Provided is a double-stranded nucleic acid complex, comprising a first nucleic acid strand and a second nucleic acid s...
|
|
WO/2022/251304A1 |
The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/251302A1 |
The present invention provides compounds useful as orexin-2 receptor agonists for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/251812A1 |
Provided herein are methods of treating a movement disorder in an individual in need thereof, comprising administering to the individual an oral dosage form of CX-8998 or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/250070A1 |
The purpose of the present invention is to provide a more effective treatment method for cancer treatment that utilizes the tumor immune system. A further purpose of the present invention is to provide, as a more effective tumor immunoth...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/250155A1 |
An oligonucleotide, which expresses a functional human WRN protein for exon 26 or exon 28 skipping mutation in human WRN gene, or a pharmaceutically acceptable salt thereof, wherein: the individual nucleotides in the oligonucleotide are ...
|
|
WO/2022/244727A1 |
The present disclosure provides a composition for improving cognitive function that comprises a fish roe lipid preparation. In one embodiment, provided is a composition for improving cognitive function that comprises a fish roe lipid pre...
|
|
WO/2022/246195A1 |
Provided herein are functional moieties, functionalized compounds and macromolecules, their preparation, and uses thereof.
|
|
WO/2022/242581A1 |
Provided herein are compounds of Formula Ia and Ib, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (R...
|
|
WO/2022/246039A1 |
Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole
or a pharmaceutically acceptable salt thereof to a subject in need the...
|
|
WO/2022/244447A1 |
The present invention addresses the problem of providing: (1) a composition that is for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting a reduction in bone density, ...
|
|
WO/2022/243973A1 |
The use of 2,4-disubstituted thiadiazolidinone (TDZD) compounds, such as Tideglusib (4-Benzyl-2-naphthalen-1-yl-[1,2,4]thiadiazolidine-3,5-dione
), in methods of inhibiting RNA molecules comprising abnormal trinucleotide repeats (such as...
|
|
WO/2022/244854A1 |
The present invention addresses the problem of providing: an antibody which can bind to CD206 and can remove a CD206-positive M2 macrophage in an adipose tissue; an agent for killing a CD206-positive M2 macrophage cell; and a pharmaceuti...
|
|
WO/2022/243651A1 |
The present invention relates to compounds of formula (I): for use in the prevention and/or treatment of cancer, autoimmune and inflammatory diseases, graft rejection and fibroses.
|
|
WO/2022/244867A1 |
The present invention relates to a composition for improving cognitive function, which contains glycine and serine, in which the weight ratio of the content of glycine to the content of serine, i.e., (glycine/serine), is 0.6 or more. A...
|
|
WO/2022/244580A1 |
Provided is an immunostimulator that contains β-glucan derived from yeast cell walls and that has a high immunostimulation effect. This immunostimulator contains β-glucan derived from yeast cell walls, and the percentage content of sai...
|
|
WO/2022/243435A1 |
The present invention relates to i) KL1333 for use in the treatment of mitochondrial diseases or diseases associated with mitochodrial diseases such as fatigue such as fatigue syndrome and fatigue associated with a disease or muscle weak...
|
